Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
- Conditions
- Overactive Bladder
- Interventions
- Device: TENS
- Registration Number
- NCT03595215
- Lead Sponsor
- Theranova, L.L.C.
- Brief Summary
This pilot clinical study, which focuses on feasibility and proof-of-principle, will be conducted in 11 female subjects (55-100 years old) with UI. Subjects will use the device three times a week for 8 weeks and complete 3-day "voiding diaries" to record instances of UI episodes and OAB quality of life.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 18
- Females
- 55-100 years old
- Have an average urinary frequency of ≥ 8 voids per 24 hours (based on a pre-treatment 3-day voiding "training" diary)
- Have self-reported bladder symptoms of more than 3 months
- Are ambulatory and able to use the toilet independently
- Have been off antimuscarinics, anticholinergics or beta-3 agonists for at least 2 weeks prior to enrollment OR on a stable dose for the prior 3 months
- Patient has urinary urge incontinence of ≥ 8 episodes from a 3-day diary (with incontinence associated at urge level moderate or severe)
- Able to provide informed consent
- Capable and willing to follow all study-related procedures
- Have primary complaint of stress urinary incontinence
- Have a pacemaker or implantable defibrillator
- Had botox injections in the bladder or pelvic floor muscles in the past 12 months
- Have a current urinary tract or vaginal infection
- Have an active implantable SNS device (InterStim & Bion)
- Have been diagnosed with peripheral neuropathy or nerve damage
- Currently pregnant
- Deemed unsuitable for enrollment in study by the investigator based on subjects' history or physical examination
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description TENS Treatment Arm TENS This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
- Primary Outcome Measures
Name Time Method Change in Urge Incontinence Episodes Baseline and 8 weeks
- Secondary Outcome Measures
Name Time Method Change in Micturitions Per Day Baseline and 8 weeks Mean number of urinary voids per day (taken over a 3-day period)
Change in Health-related Quality of Life (HRQL) Baseline and 8 weeks Change in incontinence health-related quality of life (HRQL) scores compared to pre-treatment. The survey consists of 13 questions that can be scored from 1 to 6. Lower scores correspond with better quality of life. The lowest score possible is 13 and the highest is 78.
Trial Locations
- Locations (1)
Stanford University Medical Center
🇺🇸Palo Alto, California, United States